{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:33:26Z","timestamp":1786116806054,"version":"build-2736575974"},"reference-count":122,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,6]],"date-time":"2027-08-06T00:00:00Z","timestamp":1817510400000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K23HD119271"],"award-info":[{"award-number":["K23HD119271"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clp.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:48:14Z","timestamp":1782503294000},"page":"653-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic Therapy for the Prevention and Treatment of Neonatal Sepsis"],"prefix":"10.1016","volume":"53","author":[{"given":"Sarah A.","family":"Coggins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Puopolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib1","first-page":"1","article-title":"Births: final data for 2023","volume":"64","author":"Osterman","year":"2015","journal-title":"Natl Vital Stat Rep"},{"issue":"RR-10","key":"10.1016\/j.clp.2026.05.004_bib2","first-page":"1","article-title":"Division of bacterial diseases, national Center for Immunization and Respiratory Diseases C for DC and P (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1881","article-title":"Management of infants at risk for group B streptococcal disease","volume":"144","author":"Puopolo","year":"2019","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.clp.2026.05.004_bib4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamapediatrics.2023.3664","article-title":"Antibiotic use among infants admitted to neonatal intensive care units","volume":"177","author":"Flannery","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"8","key":"10.1016\/j.clp.2026.05.004_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.semperi.2020.151325","article-title":"Antibiotic stewardship for early-onset sepsis","volume":"44","author":"Kuzniewicz","year":"2020","journal-title":"Semin Perinatol"},{"issue":"09","key":"10.1016\/j.clp.2026.05.004_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit","volume":"31","author":"Hsieh","year":"2013","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.clp.2026.05.004_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2021.08.075","article-title":"Medication use in the neonatal Intensive Care Unit and Changes from 2010 to 2018","volume":"240","author":"Stark","year":"2022","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib8","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1542\/peds.2009-1426","article-title":"Glomerular filtration rate reference values in very preterm infants","volume":"125","author":"Vieux","year":"2010","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib11","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/AOG.0000000000002236","article-title":"Committee opinion no. 712: intrapartum management of intraamniotic infection","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib12","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1097\/AOG.0000000000003668","article-title":"Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee opinion, number 797","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib13","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/AOG.0000000000003700","article-title":"Prelabor rupture of membranes: ACOG practice bulletin, number 217","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib14","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/AOG.0000000000002833","article-title":"ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib15","first-page":"604","article-title":"The epidemiology of group B streptococcal colonization in pregnancy. Vaginal infections and prematurity study group","volume":"77","author":"Regan","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2026.05.004_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5430493","article-title":"Group B streptococcus (GBS) colonization and disease among pregnant women: a historical cohort study","volume":"2019","author":"Edwards","year":"2019","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib17","doi-asserted-by":"crossref","first-page":"e200593","DOI":"10.1001\/jamapediatrics.2020.0593","article-title":"Early-onset neonatal sepsis 2015 to 2017, the rise of Escherichia coli, and the need for novel prevention strategies","volume":"174","author":"Stoll","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"May","key":"10.1016\/j.clp.2026.05.004_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.earlhumdev.2019.05.020","article-title":"The transplacental passage of commonly used intrapartum antibiotics and its impact on the newborn management: a narrative review","volume":"135","author":"Viel-Theriault","year":"2019","journal-title":"Early Hum Dev"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2018.19283","article-title":"Evaluation and management of penicillin allergy: a review","volume":"321","author":"Shenoy","year":"2019","journal-title":"JAMA, J Am Med Assoc"},{"issue":"2 Pt 1","key":"10.1016\/j.clp.2026.05.004_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/AOG.0b013e31817d0246","article-title":"Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery","volume":"112","author":"Barber","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0029-7844(97)00587-5","article-title":"Timing of intrapartum ampicillin and prevention of vertical transmission of group B streptococcus","volume":"91","author":"De","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.clp.2026.05.004_bib20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.1979.03290380021019","article-title":"Ampicillin prevents intrapartum transmission of group B streptococcus","volume":"241","author":"Yow","year":"1979","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/148.5.810","article-title":"Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. III. Interruption of mother-to-infant transmission","volume":"148","author":"Boyer","year":"1983","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jpeds.2013.05.064","article-title":"Group B streptococcal colonization in 160 mother-baby pairs: a prospective cohort study","volume":"163","author":"Berardi","year":"2013","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib23","first-page":"358","article-title":"Assessing the pharmacokinetics of ampicillin in newborns\u2019 umbilical cord blood and plasma after intrapartum administration for preventing early onset group B streptococcal infection (A prospective study)","volume":"176","author":"Hasan","year":"2025","journal-title":"Clin Ter"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/AOG.0000000000002672","article-title":"ACOG practice bulletin no. 195 summary: prevention of infection after gynecologic procedures","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2710.2007.00864.x","article-title":"Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women","volume":"32","author":"Popovi\u0107","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0029-7844(01)01629-5","article-title":"Maternal and transplacental pharmacokinetics of cefazolin","volume":"98","author":"Fiore","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib27","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1128\/AAC.01017-09","article-title":"Pharmacokinetics of clindamycin in pregnant women in the peripartum period","volume":"54","author":"Muller","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/jp.2016.122","article-title":"Transplacental passage of clindamycin from mother to neonate","volume":"36","author":"Wear","year":"2016","journal-title":"J Perinatol"},{"issue":"9","key":"10.1016\/j.clp.2026.05.004_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/pd.5753","article-title":"Pregnancy-related pharmacokinetics and antimicrobial prophylaxis during fetal surgery, cefazolin and clindamycin as examples","volume":"40","author":"Allegaert","year":"2020","journal-title":"Prenat Diagn"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib30","doi-asserted-by":"crossref","first-page":"352.e1","DOI":"10.1016\/j.ajog.2014.01.019","article-title":"Transplacental passage of vancomycin from mother to neonate","volume":"210","author":"Onwuchuruba","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/AOG.0000000000005843","article-title":"Vancomycin concentrations in umbilical cord blood after intrapartum exposure","volume":"145","author":"Coggins","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.AOG.0000151106.87930.1a","article-title":"High compared with standard gentamicin dosing for chorioamnionitis: a comparison of maternal and fetal serum drug levels","volume":"105","author":"Locksmith","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2026.05.004_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-024-03698-z","article-title":"Umbilical cord blood gentamicin concentrations following maternally-administered intrapartum exposures","author":"Coggins","year":"2024","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib34","first-page":"316","article-title":"Neonatal serum gentamicin concentrations and outcomes following maternal once-daily gentamicin dosing","volume":"28","author":"Wilson","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3S","key":"10.1016\/j.clp.2026.05.004_bib35","doi-asserted-by":"crossref","first-page":"S807","DOI":"10.1016\/j.ajog.2023.02.002","article-title":"Clinical chorioamnionitis at term: definition, pathogenesis, microbiology, diagnosis, and treatment","volume":"230","author":"Jung","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2019.100074","article-title":"Preoperative cefazolin rather than clindamycin or metronidazole is associated with lower postpartum infection among women with chorioamnionitis delivering by cesarean delivery","volume":"2","author":"Venkatesh","year":"2020","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"9","key":"10.1016\/j.clp.2026.05.004_bib39","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/psp4.70072","article-title":"Pharmacokinetics of intrapartum benzylpenicillin: insights into candidate regimens to prevent early onset neonatal group B streptococcus disease","volume":"14","author":"Obura","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib40","doi-asserted-by":"crossref","first-page":"F152","DOI":"10.1136\/archdischild-2016-312546","article-title":"Are postnatal ampicillin levels actually related to the duration of intrapartum antibiotic prophylaxis prior to delivery? A pharmacokinetic study in 120 neonates","volume":"103","author":"Berardi","year":"2018","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2005.07.098","article-title":"Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of group B streptococcus","volume":"194","author":"Colombo","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"4 I","key":"10.1016\/j.clp.2026.05.004_bib42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(96)80035-4","article-title":"Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved?","volume":"175","author":"Bloom","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/a-1674-6394","article-title":"Ampicillin pharmacokinetics in peripartum and laboring women","volume":"41","author":"Judy","year":"2024","journal-title":"Am J Perinatol"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijgo.2014.10.018","article-title":"Vaginal group B streptococcus status during intrapartum antibiotic prophylaxis","volume":"129","author":"Scasso","year":"2015","journal-title":"Int J Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib45","doi-asserted-by":"crossref","first-page":"583.e1","DOI":"10.1016\/j.ajog.2007.08.045","article-title":"The effect of intrapartum penicillin on vaginal group B streptococcus colony counts","volume":"197","author":"McNanley","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/AOG.0b013e318280d4f6","article-title":"Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease","volume":"121","author":"Fairlie","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2026.05.004_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/525878","article-title":"Duration of intrapartum antibiotics for group B streptococcus on the diagnosis of clinical neonatal sepsis","volume":"2013","author":"Turrentine","year":"2013","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib48","article-title":"Management of neonates born at \u226535 0\/7 weeks\u2019 gestation with suspected or proven early-onset bacterial sepsis","volume":"142","author":"Puopolo","year":"2018","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib49","doi-asserted-by":"crossref","first-page":"331.e1","DOI":"10.1016\/j.ajog.2012.06.064","article-title":"Transplacental transfer of vancomycin and telavancin","volume":"207","author":"Nanovskaya","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10647440400009821","article-title":"Transplacental passage of vancomycin in the ex vivo human perfusion model","volume":"12","author":"Hnat","year":"2004","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.clp.2026.05.004_bib51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14767058.2017.1306049","article-title":"Transplacental passage of vancomycin","volume":"31","author":"Towers","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1542\/peds.2013-1689","article-title":"Stratification of risk of early-onset sepsis in newborns \u226534 weeks\u2019 gestation","volume":"133","author":"Escobar","year":"2014","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib53","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-3464","article-title":"Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors","volume":"128","author":"Puopolo","year":"2011","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib55","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.03086-15","article-title":"Clindamycin pharmacokinetics and safety in preterm and term infants","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamapediatrics.2013.4248","article-title":"Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates","volume":"168","author":"Pappas","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.clp.2026.05.004_bib57","first-page":"1","article-title":"Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib58","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43691","article-title":"Analysis of antibiotic exposure and early-onset neonatal sepsis in Europe, North America, and Australia","volume":"5","author":"Giannoni","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib60","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052456","article-title":"Early-onset sepsis among very preterm infants","volume":"148","author":"Flannery","year":"2021","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamapediatrics.2016.4678","article-title":"A quantitative, risk-based approach to the management of neonatal early-onset sepsis","volume":"171","author":"Kuzniewicz","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib62","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1542\/peds.2013-1866","article-title":"2010 perinatal GBS prevention guideline and resource utilization","volume":"133","author":"Mukhopadhyay","year":"2014","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1055\/s-0041-1735220","article-title":"Early antibiotic exposure in low-risk late preterm and term infants","volume":"40","author":"Sonney","year":"2023","journal-title":"Am J Perinatol"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib64","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0164","article-title":"Temporal trends and center variation in early antibiotic use among premature infants","volume":"1","author":"Flannery","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.clp.2026.05.004_bib65","article-title":"National vital statistics report, births: final data for 2020","volume":"70","author":"Osterman","year":"2022","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clp.2026.05.004_bib69","first-page":"1","article-title":"Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management","author":"Flannery","year":"2021","journal-title":"Pediatr Res"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib66","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-058813","article-title":"Late-onset sepsis among very preterm infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.clp.2026.05.004_bib67","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jamapediatrics.2024.1840","article-title":"Hospital-onset bacteremia among neonatal intensive care unit patients","volume":"178","author":"Prochaska","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.clp.2026.05.004_bib68","volume":"40","year":"2023","journal-title":"CLSI M100-ED33: 2023 Performance Standards for Antimicrobial Susceptibility Testing"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib70","article-title":"Management of neonates born at \u226434 6\/7 weeks\u2019 gestation with suspected or proven early-onset bacterial sepsis","volume":"142","author":"Puopolo","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/adc.2009.178798","article-title":"Neonatal infections in England: the neonIN surveillance network","volume":"96","author":"Vergnano","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000003380","article-title":"Antimicrobial susceptibility profiles among neonatal early-onset sepsis pathogens","volume":"41","author":"Flannery","year":"2022","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1542\/peds.2005-0179","article-title":"Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death","volume":"117","author":"Clark","year":"2006","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib74","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1542\/peds.2005-2677","article-title":"The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants","volume":"118","author":"Cotten","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.clp.2026.05.004_bib75","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.705","article-title":"Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates","author":"Wilbaux","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib76","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0022-3476(74)80684-0","article-title":"Pharmacologic studies in neonates given large dosages of ampicillin","volume":"84","author":"Kaplan","year":"1974","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1542\/peds.39.1.97","article-title":"Clinical pharmacology of antimicrobials in premature infants: ii. ampicillin, methicillin, oxacillin, neomycin, and colistin","volume":"39","author":"Axline","year":"1967","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib79","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/BF00441533","article-title":"Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants","volume":"148","author":"Tessin","year":"1989","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib80","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1128\/AAC.02374-13","article-title":"Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design","volume":"58","author":"Tremoulet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clp.2026.05.004_bib81","doi-asserted-by":"crossref","unstructured":"AAP Committee on Infectious Diseases. Tables of antibacterial drug dosages. In: Red book: 2021\u20132024 Report of the Committee on infectious diseases (32nd Edition). ; 2021:914-932. doi:10.1542\/9781610021470-part04-tables_of_antibacterial","DOI":"10.1542\/9781610021470-part04-tables_of_antibacterial"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib82","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jpids\/piaa172","article-title":"Prolonged post-discontinuation antibiotic exposure in very low birth weight neonates at risk for early-onset sepsis","volume":"10","author":"Le","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib83","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41372-022-01344-2","article-title":"Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship","volume":"42","author":"Le","year":"2022","journal-title":"J Perinatol"},{"issue":"10","key":"10.1016\/j.clp.2026.05.004_bib84","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/00007611-198410000-00031","article-title":"Ampicillin-associated seizures","volume":"77","author":"Hodgman","year":"1984","journal-title":"South Med J"},{"issue":"8298","key":"10.1016\/j.clp.2026.05.004_bib85","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(82)90703-6","article-title":"Generalised seizures and ampicillin","volume":"320","author":"Serdaru","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.clp.2026.05.004_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2016.07.011","article-title":"Electronic health records and pharmacokinetic modeling to assess the relationship between ampicillin exposure and seizure risk in neonates","volume":"178","author":"Hornik","year":"2016","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib87","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/adc.58.11.897","article-title":"Incidence of potentially toxic concentrations of gentamicin in the neonate","volume":"58","author":"Mulhall","year":"1983","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1016\/j.clp.2026.05.004_bib88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-2002-36836","article-title":"Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen","volume":"19","author":"Avent","year":"2002","journal-title":"Am J Perinatol"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib89","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1542\/peds.103.6.1228","article-title":"Once-daily gentamicin dosing in newborn infants","volume":"103","author":"Lundergan","year":"1999","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib90","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bcp.12444","article-title":"Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates","volume":"78","author":"Fuchs","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.clp.2026.05.004_bib91","article-title":"One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates","volume":"12","author":"Rao","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib92","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/adc.2004.056317","article-title":"Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis","volume":"90","author":"Nestaas","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1592\/phco.21.1.7.34441","article-title":"A multicenter evaluation of gentamicin therapy in the neonatal intensive care unit","volume":"21","author":"Glover","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40262-014-0147-0","article-title":"Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants","volume":"53","author":"Roberts","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"August 2020","key":"10.1016\/j.clp.2026.05.004_bib95","article-title":"Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: dosing optimization for neonatal sepsis","volume":"163","author":"Li","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2025-071372","article-title":"Late antibiotic use among preterm infants admitted to the neonatal intensive care unit","volume":"156","author":"Coggins","year":"2025","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib97","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.49.7.2760-2766.2005","article-title":"Population pharmacokinetics of cefepime in the neonate","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2710.2008.00913.x","article-title":"Population pharmacokinetics of cefepime in neonates with severe nosocomial infections","volume":"33","author":"Lima-Rogel","year":"2008","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.clp.2026.05.004_bib99","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00318-07","article-title":"Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks","volume":"51","author":"Muller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02238-17","article-title":"Pharmacokinetics of penicillin G in preterm and term neonates","volume":"62","author":"Padari","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib101","article-title":"Reduction of vancomycin use in a neonatal intensive care unit: a quality improvement project","volume":"10","author":"Bhavsar","year":"2025","journal-title":"Pediatr Qual Saf"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib102","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052360","article-title":"Safety and efficacy of nafcillin for empiric therapy of late-onset sepsis in the NICU","volume":"149","author":"Magers","year":"2022","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.clp.2026.05.004_bib103","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0022-3476(78)81251-7","article-title":"Clinical and pharmacokinetic evaluation of nafcillin in infants and children","volume":"93","author":"Feldman","year":"1978","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib104","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/AAC.17.4.691","article-title":"Pharmacokinetics of nafcillin in infants with low birth weights","volume":"17","author":"Banner","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.01968-15","article-title":"Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling","volume":"60","author":"Janssen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib106","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib107","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-018-2454-0","article-title":"Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants","volume":"74","author":"Chen","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib108","first-page":"41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","author":"Kishk","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Pediatr Drugs"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib111","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"Van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.clp.2026.05.004_bib112","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: a systematic review and meta-analysis","volume":"11","author":"Ray","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib113","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Heal Pharm"},{"issue":"2","key":"10.1016\/j.clp.2026.05.004_bib114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/ejhpharm-2020-002479","article-title":"Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation","volume":"29","author":"Weng","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"10.1016\/j.clp.2026.05.004_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106958","article-title":"Association between vancomycin therapeutic drug monitoring and clinical outcomes in treating neonatal sepsis","volume":"62","author":"Chung","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.clp.2026.05.004_bib116","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ajhp\/zxad048","article-title":"Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system","volume":"80","author":"Oliver","year":"2023","journal-title":"Am J Heal Pharm"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"10.1016\/j.clp.2026.05.004_bib118","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","article-title":"Population pharmacokinetics of piperacillin using scavenged samples from preterm infants","volume":"34","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.clp.2026.05.004_bib119","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1128\/AAC.02139-13","article-title":"Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants","volume":"58","author":"Cohen-Wolkowiez","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.clp.2026.05.004_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00998-25","article-title":"Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections","volume":"70","author":"Boer-P\u00e9rez","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.clp.2026.05.004_bib121","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"Van Den Anker","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib122","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/jac\/dky128","article-title":"Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies","volume":"73","author":"Germovsek","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.clp.2026.05.004_bib123","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1111\/bcp.15308","article-title":"Optimal dose of meropenem for the treatment of neonatal sepsis: dosing guideline variations and clinical practice deviations","volume":"88","author":"Raza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clp.2026.05.004_bib124","series-title":"Meropenem for injections","first-page":"1","year":"2011"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510826000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510826000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:16:32Z","timestamp":1786018592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510826000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0095510826000527"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2026.05.004","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic Therapy for the Prevention and Treatment of Neonatal Sepsis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}